Terraflos closes $3.5M Pre-Serie A to accelerate preventive longevity across LATAM
Uruguay-based Terraflos has closed a $3.5 million Pre-Serie A funding round led by Rainforest Capital and Swiss Pampa. The round brings total capital raised to over $10 million and values the company at $85 million, positioning it among the region's most ambitious consumer biotechnology ventures.
Founded by Argentine entrepreneur Facundo Garretón, a computer engineer who previously co-founded InvertirOnline and sold it to Banco Supervielle in 2018, Terraflos integrates biotechnology, artificial intelligence, and product development around preventive longevity. The company operates three brands: Vitalis Navitas for supplements, NutriCo for functional foods, and Aurelis for skincare and cosmetics.
Terraflos maintains headquarters in Uruguay while keeping roughly half its workforce in Argentina. The company formalized its Argentine presence in 2024 by acquiring Mar del Plata-based Vitalis Navitas, which brought over 150,000 customers and established production infrastructure. The new funding will support regional expansion, strengthen the scientific platform, and broaden production capabilities across the brand ecosystem.
Why Terraflos's dual Argentina-Uruguay expansion signals biotech talent demand in the Cono Sur
The company's binational structure reflects strategic workforce planning in a region where scientific and technical talent concentrates in specific hubs. The Vitalis Navitas acquisition served dual purposes: it provided market access and customer base while securing Mar del Plata's production infrastructure and local expertise in natural products formulation.
Need help hiring?
See the next step after this guide
If this topic is relevant to your team, these are the most useful pages to check next.
Operating across two countries creates distinct hiring pressures. Companies scaling biotech and AI-driven consumer science recruitment must navigate separate regulatory environments, manage payroll across different tax and labor frameworks, and coordinate teams split between Montevideo and Argentine cities. The acquisition demonstrates how M&A can accelerate both market entry and talent acquisition when organic hiring faces constraints.
Each of Terraflos's three brands demands specialized skill sets. Vitalis Navitas produces nutritional supplements. NutriCo develops plant-based superfoods using scientific evidence and artificial intelligence. Aurelis addresses skincare and cosmetics. All three require expertise in formulation chemistry, regulatory compliance, quality control, and consumer product development.
The company's emphasis on combining biotechnology with AI for product development signals ongoing demand for data scientists, machine learning engineers, and bioinformatics specialists capable of working at the intersection of consumer goods and life sciences. These roles remain scarce in Latin America, where biotech startups compete with fintech and software companies for technical talent. The valuation positions Terraflos to offer competitive compensation packages in markets where biotech salaries have historically lagged behind technology sector benchmarks.
GENTY's scaling biotech talent across Argentina guide offers additional context for employers planning their next hires. GENTY's biotech and AI-driven consumer science recruitment guide offers additional context for employers planning their next hires.
Scaling scientific talent as consumer biotech startups compete for LATAM market leadership
The preventive longevity sector represents one of the fastest-growing segments globally, and Terraflos's funding round signals investor confidence that Latin American startups can compete beyond regional markets. However, scaling scientific operations presents distinct challenges compared to software-based ventures.
Biotech companies require personnel with advanced degrees in chemistry, biology, and nutrition science. They need regulatory affairs specialists familiar with health authority requirements across multiple countries. Quality assurance teams must ensure compliance with good manufacturing practices. These roles cannot be filled as rapidly as software engineering positions, creating potential bottlenecks as funded startups expand.
Terraflos's vertical integration strategy, encompassing ingredient development through final product commercialization, multiplies staffing requirements. The company must maintain R&D teams developing novel formulations, production staff managing manufacturing, and commercial teams handling distribution across three separate brand identities.
For employers in biotech and consumer health, Terraflos's trajectory offers practical lessons. Cross-border expansion within the Cono Sur provides access to complementary talent pools and regulatory opportunities. Acquisition-driven growth can accelerate team building when organic hiring faces constraints. Companies positioning at the intersection of biotechnology and artificial intelligence must compete for talent against both traditional life sciences firms and technology startups.
The participation of funds including Rainforest Capital and Swiss Pampa suggests that capital availability for biotech ventures in the region is improving. This funding environment will likely intensify competition for qualified scientific and technical professionals as more startups pursue similar consumer health strategies.
As Terraflos executes its expansion plans, its hiring patterns and operational scaling will test whether the Cono Sur can support multiple high-growth biotech employers simultaneously or whether talent constraints will favor consolidation.